Genetic and epigenetic changes in vulvar squamous cell carcinoma and its precursor lesions: A review of the current literature

Gynecologic Oncology

Volumn 136, Issue 1, 2015, Pages 143-157

  Trietsch, Marjolijn D ^a   Nooij, Linda S ^a   Gaarenstroom, Katja N ^a   Van Poelgeest, Mariette I E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epigenetic; Genetic; Intraepithelial neoplasia; Somatic mutations; Squamous cell carcinoma; Vulva

Indexed keywords

REPETITIVE DNA;

ALLELIC IMBALANCE; ARTICLE; COPY NUMBER VARIATION; DNA METHYLATION; EPIGENETICS; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; SOMATIC MUTATION; SQUAMOUS CELL CARCINOMA; VULVA CARCINOMA; VULVAR SQUAMOUS CELL CARCINOMA; WART VIRUS; FEMALE; GENETICS; PRECANCER; VULVA TUMOR;

CARCINOMA, SQUAMOUS CELL; EPIGENOMICS; FEMALE; HUMANS; PRECANCEROUS CONDITIONS; VULVAR NEOPLASMS;

EID: 84925230215     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.11.002     Document Type: Review

References (81)

1. Del Pino M, Rodriguez-Carunchio L, Ordi J. Pathways of vulvar intraepithelial neoplasia and squamous cell carcinoma. Histopathology Jan 2013;62(1):161-75.
2. Gadducci A, Tana R, Barsotti C, Guerrieri ME, Genazzani AR. Clinico-pathological and biological prognostic variables in squamous cell carcinoma of the vulva. Crit Rev Oncol Hematol Jul 2012;83(1):71-83.
3. van der Avoort IA, Shirango H, Hoevenaars BM, Grefte JM, de Hullu JA, de Wilde PC, et al. Vulvar squamous cell carcinoma is a multifactorial disease following two separate and independent pathways. Int J Gynecol Pathol Jan 2006;25(1):22-9.
4. Schuurman MS, van den Einden LC, Massuger LF, Kiemeney LA, van der Aa MA, de Hullu JA. Trends in incidence and survival of Dutch women with vulvar squamous cell carcinoma. Eur J Cancer Dec 2013;49(18):3872-80.
5. van de Nieuwenhof HP, Massuger LF, van der Avoort IA, Bekkers RL, Casparie M, Abma W, et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur J Cancer Mar 2009;45(5):851-6.
6. McCluggage WG. Premalignant lesions of the lower female genital tract: cervix, vagina and vulva. Pathology Apr 2013;45(3):214-28.
7. Raspollini MR, Asirelli G, Moncini D, Taddei GL. A comparative analysis of lichen sclerosus of the vulva and lichen sclerosus that evolves to vulvar squamous cell carcinoma. Am J Obstet Gynecol Dec 2007;197(6):592-5.
8. Pinto AP, Miron A, Yassin Y, Monte N, Woo TY, Mehra KK, et al. Differentiated vulvar intraepithelial neoplasia contains Tp53 mutations and is genetically linked to vulvar squamous cell carcinoma. Mod Pathol Mar 2010;23(3):404-12.
9. Hantschmann P, Sterzer S, Jeschke U, Friese K. P53 expression in vulvar carcinoma, vulvar intraepithelial neoplasia, squamous cell hyperplasia and lichen sclerosus. Anticancer Res May 2005;25(3A):1739-45.
10. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: aspects of the natural history and outcome in 405 women. Obstet Gynecol Dec 2005;106(6): 1319-26.
11. Jones RW, Rowan DM. Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. Obstet Gynecol Nov 1994;84(5):741-5.
12. Rolfe KJ, Eva LJ, MacLean AB, Crow JC, Perrett CW, Reid WM. Cell cycle proteins as molecular markers of malignant change in vulvar lichen sclerosus. Int J Gynecol Cancer Mar 2001;11(2):113-8.
13. Kokka F, Singh N, Faruqi A, Gibbon K, Rosenthal AN. Is differentiated vulval intraepithelial neoplasia the precursor lesion of human papillomavirus-negative vulval squamous cell carcinoma? Int J Gynecol Cancer Oct 2011;21(7):1297-305.
14. Gonzalez BJ, Magrina JF, Gaffey TA, Hernandez JL, Webb MJ, Cliby WA, et al. Longterm survival and disease recurrence in patients with primary squamous cell carcinoma of the vulva. Gynecol Oncol Jun 2005;97(3):828-33.
15. Coulter J, Gleeson N. Local and regional recurrence of vulval cancer: management dilemmas. Best Pract Res Clin Obstet Gynaecol Aug 2003;17(4):663-81.
16. Cormio G, Loizzi V, Carriero C, Cazzolla A, Putignano G, Selvaggi L. Groin recurrence in carcinoma of the vulva: management and outcome. Eur J Cancer Care (Engl) May 2010;19(3):302-7.
17. Hopkins MP, Reid GC, Morley GW. The surgical management of recurrent squamous cell carcinoma of the vulva. Obstet Gynecol Jun 1990;75(6):1001-5.
18. Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A Jun 24 2008; 105(25):8713-7.
19. Gasche JA, Goel A. Epigenetic mechanisms in oral carcinogenesis. Future Oncol Nov 2012;8(11):1407-25.
20. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, et al. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol Mar 2013;128(3):409-14.
21. Santarpia L, Qi Y, Stemke-Hale K, Wang B, Young EJ, Booser DJ, et al. Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers. Breast Cancer Res Treat Jul 2012; 134(1):333-43.
22. Wegman P, Ahlin C, Sorbe B. Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy. Int J Gynecol Cancer Jan 2011;21(1):86-91.
23. Worsham MJ, Chen KM, Meduri V, Nygren AO, Errami A, Schouten JP, et al. Epigenetic events of disease progression in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg Jun 2006;132(6):668-77.
24. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med Jun 30 2011;364(26):2507-16.
25. Choschzick M, Hantaredja W, Tennstedt P, Gieseking F, Wolber L, Simon R. Role of TP53 mutations in vulvar carcinomas. Int J Gynecol Pathol Sep 2011;30(5):497-504.
26. Rolfe KJ, MacLean AB, Crow JC, Benjamin E, Reid WM, Perrett CW. TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva. Br J Cancer Dec 15 2003;89(12):2249-53.
27. Holway AH, Rieger-Christ KM, Miner WR, Cain JW, Dugan JM, Pezza JA, et al. Somatic mutation of PTEN in vulvar cancer. Clin Cancer Res Aug 2000;6(8):3228-35.
28. Soufir N, Queille S, Liboutet M, Thibaudeau O, Bachelier F, Delestaing G, et al. Inactivation of the CDKN2A and the p53 tumour suppressor genes in external genital carcinomas and their precursors. Br J Dermatol Mar 2007;156(3):448-53.
29. Aide S, Lattario FR, Almeida G, do Val IC, Carvalho MG. Promoter hypermethylation of death-associated protein kinase and p16 genes in vulvar lichen sclerosus. J Low Genit Tract Dis Apr 2012;16(2):133-9.
30. Guerrero D, Guarch R, Ojer A, Casas JM, Mendez-Meca C, Esteller M, et al. Differential hypermethylation of genes in vulvar cancer and lichen sclerosus coexisting or not with vulvar cancer. Int J Cancer Jun 15 2011;128(12):2853-64.
31. Kelemen LE, Kobel M, Chan A, Taghaddos S, Dinu I. Differentially methylated loci distinguish ovarian carcinoma histological types: evaluation of a DNA methylation assay in FFPE tissue 39. Biomed Res Int 2013;2013:815894.
32. Smith ZD, Chan MM, Mikkelsen TS, Gu H, Gnirke A, Regev A, et al. A unique regulatory phase of DNA methylation in the early mammalian embryo. Nature Apr 19 2012;484(7394):339-44.
33. Gasco M, Sullivan A, Repellin C, Brooks L, Farrell PJ, Tidy JA, et al. Coincident inactivation of 14-3-3sigma and p16INK4a is an early event in vulval squamous neoplasia. Oncogene Mar 14 2002;21(12):1876-81.
34. O'Nions J, Brooks LA, Sullivan A, Bell A, Dunne B, Rozycka M, et al. p73 is overexpressed in vulval cancer principally as the Delta 2 isoform. Br J Cancer Nov 16 2001;85(10):1551-6.
35. Gambichler T, Terras S, Kreuter A, Skrygan M. Altered global methylation and hydroxymethylation status in vulvar lichen sclerosus - further support for epigenetic mechanisms. Br J Dermatol Oct 27 2013;170(3):687-93.
36. Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, et al. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecol Oncol Nov 2008;111(2):289-97.
37. Pilotti S, Donghi R, D'Amato L, Giarola M, Longoni A, Della TG, et al. HPV detection and p53 alteration in squamous cell verrucous malignancies of the lower genital tract. Diagn Mol Pathol Dec 1993;2(4):248-56.
38. Kurvinen K, Tervahauta A, Syrjanen S, Chang F, Syrjanen K. The state of the p53 gene in human papillomavirus (HPV)-positive and HPV-negative genital precancer lesions and carcinomas as determined by single-strand conformation polymorphism analysis and sequencing. Anticancer Res Jan 1994;14(1A):177-81.
39. Lee YY, Wilczynski SP, Chumakov A, Chih D, Koeffler HP. Carcinoma of the vulva: HPV and p53 mutations. Oncogene Jun 1994;9(6):1655-9.
40. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer Nov 27 1995;63(5):639-45.
41. Pilotti S, D'Amato L, Della TG, Donghi R, Longoni A, Giarola M, et al. Papillomavirus, p53 alteration, and primary carcinoma of the vulva. Diagn Mol Pathol Dec 1995; 4(4):239-48.
42. Kim YT, Thomas NF, Kessis TD, Wilkinson EJ, Hedrick L, Cho KR. p53 mutations and clonality in vulvar carcinomas and squamous hyperplasias: evidence suggesting that squamous hyperplasias do not serve as direct precursors of human papillomavirusnegative vulvar carcinomas. Hum Pathol Apr 1996;27(4):389-95.
43. Sliutz G, Schmidt W, Tempfer C, Speiser P, Gitsch G, Eder S, et al. Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis. Gynecol Oncol Jan 1997;64(1):93-8.
44. Wong YF, Chung TK, Cheung TH, Nobori T, Yim SF, Lai KW, et al. p16INK4 and p15INK4B alterations in primary gynecologic malignancy. Gynecol Oncol May 1997;65(2):319-24.
45. Flowers LC, Wistuba II, Scurry J, Muller CY, Ashfaq R, Miller DS, et al. Genetic changes during the multistage pathogenesis of human papillomavirus positive and negative vulvar carcinomas. J Soc Gynecol Investig Jul 1999;6(4):213-21.
46. Ngan HY, Cheung AN, Liu SS, Yip PS, Tsao SW. Abnormal expression or mutation of TP53 and HPV in vulvar cancer. Eur J Cancer Mar 1999;35(3):481-4.
47. Brooks LA, Tidy JA, Gusterson B, Hiller L, O'Nions J, Gasco M, et al. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res Dec 15 2000; 60(24):6875-7.
48. Marin MC, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet May 2000; 25(1):47-54.
49. Wada H, Enomoto T, Yoshino K, Ozaki K, Kurachi H, Nomura T, et al. Immunohistochemical localization of telomerase hTERT protein and analysis of clonality in multifocal vulvar intraepithelial neoplasia. Am J Clin Pathol Sep 2000; 114(3):371-9.
50. Rampone A, Vozza G, Vozza A, Rampone B, Capuano I, Tirabasso S, et al. Lichen and vulvar cancer. Personal experience. [Italian] I lichen ed il carcinoma vulvare. Nostra esperienza. G Ital Dermatol Venereol Aug 2002;137(4):267-9.
51. Reddy A, Yuille M, Sullivan A, Repellin C, Bell A, Tidy JA, et al. Analysis of CHK2 in vulval neoplasia. Br J Cancer Mar 4 2002;86(5):756-60.
52. Vanin K, Scurry J, Thorne H, Yuen K, Ramsay RG. Overexpression of wild-type p53 in lichen sclerosus adjacent to human papillomavirus-negative vulvar cancer. J Invest Dermatol Nov 2002;119(5):1027-33.
53. Almeida G, do V I, Gondim C, Lima R, Takiya C, Carvalho G. Human papillomavirus, Epstein-Barr virus and p53 mutation in vulvar intraepithelial neoplasia. J Reprod Med Oct 2004;49(10):796-9.
54. Chulvis do Val IC, Almeida Filho GL, Valiante PM, Gondim C, Takiya CM, Carvalho MG. Vulvar intraepithelial neoplasia p53 expression, p53 gene mutation and HPV in recurrent/progressive cases. J Reprod Med Nov 2004;49(11):868-74.
55. Olawaiye A, Lee LM, Krasner C, Horowitz N. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol 2007; 106(3):628-30.
56. Osakabe M, Hayashi M, Katayama Y, Emura I, Nemoto K, Umezu H, et al. Characteristics of vulvar squamous cell carcinoma in Japanese women. Pathol Int Jun 2007; 57(6):322-7.
57. Tapp RA, Feng J, Jones JW, Carlson JA, Wilson VL. Single base instability is promoted in vulvar lichen sclerosus. J Invest Dermatol Nov 2007;127(11):2563-76.
58. Aulmann S, Schleibaum J, Penzel R, Schirmacher P, Gebauer G, Sinn HP. Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. J Clin Pathol Sep 2008;61(9):1034-7.
59. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, et al. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther Mar 2011;10(3):558-65.
60. Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol Oct 2012;127(1):141-6.
61. Trietsch MD, Spaans VM, Ter Haar NT, Osse EM, Peters AA, Gaarenstroom KN, et al. CDKN2A (p16) and HRAS are frequently mutated in vulvar squamous cell carcinoma 1. Gynecol Oncol Jul 26 2014;135(1):149-55.
62. Scheistroen M, Trope C, Pettersen EO, Nesland JM. p53 protein expression in squamous cell carcinoma of the vulva. Cancer 1999;85(5):1133-8.
63. Bryndorf T, Kirchhoff M, Larsen J, Andreasson B, Bjerregaard B, Westh H, et al. The most common chromosome aberration detected by high-resolution comparative genomic hybridization in vulvar intraepithelial neoplasia is not seen in vulvar squamous cell carcinoma. Cytogenet Genome Res 2004;106(1):43-8.
64. Micci F, Panagopoulos I, Haugom L, Dahlback H-S, Pretorius ME, Davidson B, et al. Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva. Genes Chromosomes Cancer Jun 2013;52(6):551-63.
65. Lin MC, Mutter GL, Trivijisilp P, Boynton KA, Sun D, Crum CP. Patterns of allelic loss (LOH) in vulvar squamous carcinomas and adjacent noninvasive epithelia 1. Am J Pathol May 1998;152(5):1313-8.
66. Pinto AP, Lin M-C, Mutter GL, Sun D, Villa LL, Crum CP. Allelic loss in human papillomavirus-positive and -negative vulvar squamous cell carcinomas. Am J Pathol Apr 1999;154(4):1009-15.
67. Carlson JA, Healy K, Tran TA, Malfetano J, Wilson VL, Rohwedder A, et al. Chromosome 17 aneusomy detected by fluorescence in situ hybridization in vulvar squamous cell carcinomas and synchronous vulvar skin. Am J Pathol 2000;157(3): 973-83.
68. Jee KJ, Kim YT, Kim KR, Kim HS, Yan A, Knuutila S. Loss in 3p and 4p and gain of 3q are concomitant aberrations in squamous cell carcinoma of the vulva. Mod Pathol 2001;14(5):377-81.
69. Allen DG, Hutchins AM, Hammet F, White DJ, Scurry JP, Tabrizi SN, et al. Genetic aberrations detected by comparative genomic hybridisation in vulvar cancers. Br J Cancer Mar 18 2002;86(6):924-8.
70. Rosenthal AN, Ryan A, Hopster D, Surentheran T, Jacobs IJ. High frequency of loss of heterozygosity in vulval intraepithelial neoplasia (VIN) is associated with invasive vulval squamous cell carcinoma (VSCC). Int J Cancer Dec 15 2001; 94(6):896-900.
71. Huang FY, Kwok YKY, Lau ET, Tang MHY, Ng TY, Ngan HYS. Genetic abnormalities and HPV status in cervical and vulvar squamous cell carcinomas. Cancer Genet Cytogenet Feb 2005;157(1):42-8.
72. Yangling O, Shulang Z, Rongli C, Bo L, Lili C, Xin W. Genetic imbalance and human papillomavirus states in vulvar squamous cell carcinomas. Eur J Gynaecol Oncol 2007;28(6):442-6.
73. Lavorato-Rocha AM, De Melo MB, Rodrigues IS, Stiepcich MMA, Baiocchi G, Cestari FMDS, et al. Prognostication of vulvar cancer based on p14ARF status: molecular assessment of transcript and protein. Ann Surg Oncol Jan 2013; 20(1):31-9.
74. Bujko M, Kowalewska M, Zub R, Radziszewski J, Bidzinski M, Siedlecki JA. Lack of microsatellite instability in squamous cell vulvar carcinoma. Acta Obstet Gynecol Scand Mar 2012;91(3):391-4.
75. Pinto AP, Lin MC, Sheets EE, Muto MG, Sun D, Crum CP. Allelic imbalance in lichen sclerosus, hyperplasia, and intraepithelial neoplasia of the vulva. Gynecol Oncol Apr 2000;77(1):171-6.
76. Aide S, Lattario FR, Almeida G, do Val IC, Carvalho MG. Promoter hypermethylation patterns of death-associated protein kinase and p16 genes in vulvar lichen sclerosus. J Low Genit Tract Dis Oct 2010;14(4):282-6.
77. Guerrero-Setas D, Perez-Janices N, Ojer A, Blanco-Fernandez L, Guarch-Troyas C, Guarch R. Differential gene hypermethylation in genital lichen sclerosus and cancer: a comparative study. Histopathology Nov 2013;63(5):659-69.
78. Lerma E, Esteller M, Herman JG, Prat J. Alterations of the p16 (INK4a)/Rb/Cyclin-D1 pathway in vulvar carcinoma, vulvar intraepithelial neoplasia, and lichen sclerosus. Hum Pathol 2002;33(11):1120-5.
79. Oonk MH, Eijsink JJ, Volders HH, Hollema H, Wisman GB, Schuuring E, et al. Identification of inguinofemoral lymph node metastases by methylation markers in vulvar cancer. Gynecol Oncol May 2012;125(2):352-7.
80. Rosenthal AN, Hopster D, Ryan A, Jacobs IJ. Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma. Br J Cancer Jan 27 2003;88(2):251-6.
81. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med Mar 2011;17(3):330-9.